2021
DOI: 10.1016/j.ijrobp.2021.07.1185
|View full text |Cite
|
Sign up to set email alerts
|

Oropharyngeal Cancer Early Outcomes and Challenges During the COVID-19 Pandemic

Abstract: Purpose/Objective(s) The COVID-19 pandemic triggered a national emergency which drastically affected the practice of medicine. Studies have already shown that delays in cancer screening/diagnosis/treatment have ensued, and some project this will translate into increased mortality. We aimed to evaluate if early oropharyngeal cancer (OPC) outcomes with radiation therapy (RT) were affected. Materials/Methods On 3/17/2020, in response to the crisis in New York City, telemed… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
1
1
0
Order By: Relevance
“…Despite the reduced number of HPV+ OPC patients seen during the Pandemic period, they often presented with more advanced neck disease (N2-N3), higher overall stage, and a non-significant trend towards more T4 disease (p=0.059). Our findings are consistent with the results from other reports in the head and neck cancer population [10] , [11] , [12] . More advanced disease at presentation could explain the trend toward more frequent use of systemic agents in the Pandemic cohort; ultimately, this would impact health care resources and toxicity of treatment.…”
Section: Discussionsupporting
confidence: 94%
“…Despite the reduced number of HPV+ OPC patients seen during the Pandemic period, they often presented with more advanced neck disease (N2-N3), higher overall stage, and a non-significant trend towards more T4 disease (p=0.059). Our findings are consistent with the results from other reports in the head and neck cancer population [10] , [11] , [12] . More advanced disease at presentation could explain the trend toward more frequent use of systemic agents in the Pandemic cohort; ultimately, this would impact health care resources and toxicity of treatment.…”
Section: Discussionsupporting
confidence: 94%
“…Non-COVID-19 related clinician and patient factors also contributed to delays in in both Pandemic and Pre-Pandemic cohorts, and this is also worth studying to improve care of our HN cancer patients' care. 4,[17][18][19][20] Despite our findings of increased COVID-19-related delays in the assessments and diagnosis of HN patients and more advanced disease at presentation, it is important to note that this does not necessarily suggest that alternative policies would have been preferable. It is impossible to know what "would have been" had these changes not occurred.…”
Section: Discussionmentioning
confidence: 99%